Archives
-
Fluorescein Tyramide for Oxytocin Circuit Assays
2026-09-16
Fluorescein Tyramide enables sensitive spatial validation of oxytocin signaling in neural tissue. This article translates recent early-life-adversity findings into practical choices for IHC, ISH, and flow cytometry assay design, with emphasis on controls and interpretability.
-
Axitinib (AG 013736) Assay Workflow Guide
2026-09-15
Build more informative angiogenesis and cancer-response experiments with Axitinib (AG 013736), from VEGFR pathway engagement to xenograft study design. The workflow separates pathway-specific inhibition from general growth arrest or cell death, improving interpretation and reproducibility.
-
GKT137831 for Reliable Redox Cell Assays
2026-09-15
This scenario-based guide explains how GKT137831, SKU B4763, can improve interpretation of viability, proliferation, and oxidative-stress assays. It connects Nox1/Nox4 inhibition with practical solvent, dosing, controls, and ferroptosis-related experimental considerations.
-
Genotyping Kit for target alleles: Workflow Guide
2026-09-14
SKU K1026 streamlines single-tube genomic DNA preparation for PCR-based allele screening across insects, tissues, fishes, and cultured cells. This guide connects practical genotyping workflows with the E-cadherin and NR1I3 findings reported in a DSS-colitis study, while emphasizing assay controls, troubleshooting, and the limits of direct-lysate PCR.
-
Nuclear cGAS, CHK2, and LINE-1 Control
2026-09-14
The reference study identifies a nuclear cGAS–CHK2–TRIM41 pathway that limits LINE-1 retrotransposition by promoting ubiquitination and degradation of the LINE-1 protein ORF2p. Its findings connect DNA damage signaling with post-translational control of mobile genetic elements, offering a mechanistic framework for genome integrity, aging, and cancer research.
-
Morin, AMPD2, and Podocyte Energy Metabolism
2026-09-13
A 2025 study identifies AMPD activity, particularly the AMPD2-linked purine nucleotide cycle, as a mechanistic driver of fructose-associated podocyte mitochondrial dysfunction. Using cellular and rat models, the authors show that Morin improves mitochondrial and glomerular injury phenotypes, while highlighting AMPD2 as a potential target for further kidney disease research.
-
L. plantarum P101, AMPK, and Alcoholic Steatosis
2026-09-12
A 2025 mouse study shows that Lactiplantibacillus plantarum P101 reduced alcohol-induced hepatic lipid accumulation in association with AMPK activation, while pharmacological AMPK inhibition weakened these benefits. Integrated microbiota and serum metabolomics analyses further linked the response to specific bacterial taxa and stercobilinogen, providing a systems-level framework for studying probiotic effects in alcoholic fatty liver disease.
-
GKT137831 for Nox1/Nox4 Oxidative Stress Workflows
2026-09-11
GKT137831 provides a practical dual-target strategy for connecting Nox1/Nox4 activity with hydrogen peroxide signaling, vascular remodeling, fibrosis, and metabolic disease models. This workflow-focused guide shows how to control dosing, interpret ROS and proliferation readouts, and extend redox experiments toward membrane damage and ferroptosis without overstating the evidence.
-
Firefly Luciferase mRNA: Reporter Workflow & Evidence
2026-09-11
Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) is a modified, capped reporter transcript for monitoring transfection and protein expression. Its luciferase output depends on enzyme expression, D-luciferin availability, ATP, oxygen, and assay conditions, so it is a sensitive readout rather than a standalone viability measurement.
-
GANT61 in ALK-Positive Anaplastic Large Cell Lymphoma
2026-09-10
A 2026 Annals of Hematology study identifies a potential Hh–PIK3IP1–Akt signaling connection in ALK-positive anaplastic large cell lymphoma. Its integrated proliferation, flow-cytometric, transcriptomic, and molecular analyses suggest that GANT61 suppresses growth by inhibiting Gli1, increasing PIK3IP1, and attenuating Akt activation.
-
Esflurbiprofen and Fast-Onset Antidepressant Action
2026-09-10
The reference study identifies esflurbiprofen as a candidate fast-onset antidepressant by showing that it disrupts the SERT–nNOS complex in the dorsal raphe nucleus. Its combination of mBRET-based screening, stress-model pharmacology, and rs-fMRI offers a useful framework for connecting protein-interaction modulation with circuit-level and behavioral outcomes.
-
GLP-1 (9-36) Amide in GLP-1R Research
2026-09-09
GLP-1 (9-36) amide is a peptide antagonist used to interrogate human GLP-1 receptor signaling. Its defined formulation, solvent limitations, and distinction from exendin(9-39) make careful controls essential for metabolic regulation studies and type 2 diabetes research.
-
Porcupine Inhibition in Sclerosteosis
2026-09-09
Dreyer and colleagues investigate PORCN inhibition as a pharmacological strategy for sclerosteosis, an ultra-rare high-bone-mass disorder caused by loss of functional sclerostin. Their in vitro and mouse data indicate that LGK974 suppresses excessive Wnt-associated osteoblast activity and reduces selected skeletal overgrowth measures without directly reducing osteoclast activity.
-
EZ Cap Cy5 Firefly Luciferase mRNA Workflow
2026-09-08
Track both where an mRNA goes and whether it produces functional protein with one dual-reporter reagent. This workflow combines Cy5 fluorescence for delivery analysis with luciferase bioluminescence for translation, making formulation screening and assay troubleshooting more informative.
-
LGK-974: A Practical PORCN Inhibitor Workflow
2026-09-08
Learn how to use LGK-974 as a precise upstream Wnt signaling pathway inhibitor in cell-based, pancreatic cancer, and in vivo studies. The workflow combines pathway readouts with proliferation, migration, and EMT assays to distinguish true Wnt dependence from nonspecific growth effects.